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Abstract
Background:  In 2006, a new rotavirus vaccine (RotaTeq) was licensed in the US and
recommended for routine immunization of all US infants. Because a previously licensed vaccine
(Rotashield) was withdrawn from the US for safety concerns, identifying barriers to uptake of
RotaTeq will help develop strategies to broaden vaccine coverage.
Methods: We explored beliefs and attitudes of parents (n = 57) and providers (n = 10) towards
rotavirus disease and vaccines through a qualitative assessment using focus groups and in-depth
interviews.
Results:  All physicians were familiar with safety concerns about rotavirus vaccines, but felt
reassured by RotaTeq's safety profile. When asked about likelihood of using RotaTeq on a scale of
one to seven (1 = "absolutely not;" 7 = "absolutely yes") the mean score was 5 (range = 3–6).
Physicians expressed a high likelihood of adopting RotaTeq, particularly if recommended by their
professional organizations and expressed specific interest in post-marketing safety data. Similarly,
consumers found the RotaTeq safety profile to be favorable and would rely on their physician's
recommendation for vaccination. However, when asked to rank likelihood of having their child
vaccinated against rotavirus (1 = "definitely not get;" 7 = "definitely get"), 29% ranked 1 or 2, 36%
3 or 4, and 35% 5 to 7.
Conclusion: Our qualitative assessment provides complementary data to recent quantitative
surveys and suggests that physicians and parents are likely to adopt the newly licensed rotavirus
vaccine. Increasing parental awareness of the rotavirus disease burden and providing physicians
with timely post-marketing surveillance data will be integral to a successful vaccination program.
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Background
In February 2006, a new rotavirus vaccine (RotaTeq,
Merck) was licensed by the US Food and Drug Adminis-
tration (FDA) and was recommended by the Advisory
Committee on Immunization Practices (ACIP) for routine
immunization of all US infants at 2, 4, and 6 months of
age[1]. This vaccine, which in clinical trials demonstrated
an efficacy of 74% against any rotavirus disease and 98%
against severe rotavirus disease,[2] holds great promise for
the prevention of the more than 2.7 million episodes of
diarrhea, 400,000 outpatient office visits, and
55,000–70,000 hospitalizations per year attributable to
rotavirus in US children <5 years of age [3]. Identifying
barriers to uptake of this vaccine will help policy makers
and public health officials develop strategies to achieve
high immunization rates for optimum disease prevention
efforts.
A well-recognized potential barrier to acceptance of
RotaTeq is the association of a previous rotavirus vaccine
(Rotashield, Wyeth Laboratories) with intussusception, a
potentially life-threatening intestinal blockage [4-6].
Because of this adverse event, Rotashield was withdrawn
from the market less than a year after its introduction in
August 1998[4,5]. Although RotaTeq has not been associ-
ated with intussusception or other serious adverse events
in large pre-licensure clinical trials [1,2], the abrupt with-
drawal of Rotashield garnered considerable nationwide
attention and could affect adoption of the vaccine by par-
ents and healthcare workers. In a national survey of US
pediatricians, possible reluctance of parents to accept the
new vaccine because of the safety issues associated with
Rotashield was indeed identified as a potential major bar-
rier to acceptance [6,7]. However, a limitation of struc-
tured quantitative surveys is that the questions may not
have allowed for a complete disclosure of all issues and
beliefs with regard to rotavirus vaccination [8]. In addi-
tion, to our knowledge, no direct assessment of the atti-
tudes and beliefs of parents towards the rotavirus vaccine
has been conducted.
To directly explore the beliefs and attitudes of parents of
US children towards rotavirus vaccines and to gain further
insight into the providers' concerns, we conducted a qual-
itative study of prospective providers and consumers of
the rotavirus vaccine. Our objectives were to identify
issues and concerns related to rotavirus disease and vacci-
nations among both providers and consumers so that we
can develop strategies for improving adoption of the new
rotavirus vaccine.
Methods
Sample and data collection
Our study sample consisted of two groups: healthcare pro-
viders and consumers. Study participants went through
the same study process at two different locations: Sunny-
vale, California and Kansas City, Missouri.
Providers
Physician participants were recruited by market research
firms that were asked to contact actively practicing, non-
military, non-institutional physicians who practice in
their communities. Participants were further screened,
limiting selection to board-certified or board-eligible
pediatricians or family medicine physicians who typically
administer 5 or more immunizations each week. At each
of the two study sites, we enrolled a minimum of one
pediatrician and one family medicine practitioner who
had been in practice for 10 years or longer to ensure par-
ticipation of a provider who was practicing during the
period when Rotashield was withdrawn. We excluded par-
ticipants if an immediate family member worked in
advertising, public relations, marketing research, or the
media.
Because our primary interest regarding providers was their
personal experience and perspective on rotavirus disease
and vaccines (i.e., Rotashield and RotaTeq), we choose to
conduct in-depth interviews as the data collection method
for this group. A moderator with over 25 years of experi-
ence conducted individual 60-minute interviews using a
guide that facilitated the discussion. In general, after intro-
duction of the project, the moderator asked each provider
to discuss his/her treatment algorithm for a typical child
who presents to his/her clinic with diarrhea. Subse-
quently, the provider was prompted to discuss issues per-
taining to the previous Rotashield vaccine. The moderator
then asked the provider to review the FDA package insert
with information on the recently introduced RotaTeq vac-
cine. Issues relating to the safety, acceptability, and future
utilization of RotaTeq were explored. Lastly, each provider
reviewed the rotavirus Vaccine Information Statement, a
CDC public information sheet on rotavirus disease and
vaccines, and was asked to render his/her opinion about
patient-education materials.
Consumers
Consumer groups were recruited from a panel of persons
that had previously indicated an interest in participating
in focus groups. For this group, we recruited women older
than 18 years who reported themselves as "likely or very
likely" to give birth to a child within 4 years and expressed
intent to have their child receive routine vaccinations
against childhood diseases. We excluded women who
were employed in the healthcare field or in the media or
who had participated in any market studies within the
previous six months.
We convened four 90-minute focus groups in each study
site. Women were categorized according to their child-BMC Pediatrics 2007, 7:32 http://www.biomedcentral.com/1471-2431/7/32
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rearing (CR) experience (experience raising > one child to
age 6) and their level of concern (LOC) regarding the
safety of childhood vaccinations (i.e., high = self-reported
as being "very" or "moderately" concerned; low = self-
reported as having "no" or "a little" concern). The four
focus groups were a combination of women in these two
categories (e.g., group 1: LOC = high and CR = yes). We
ensured that each group consisted of > 2 participants with
less than a Bachelor's degree of formal education and > 2
participants with a Bachelor's degree or more of formal
education.
After introduction to the project, each focus group began
with a discussion of the general childhood health con-
cerns that the participants regarded to be important. The
discussion subsequently was directed to diarrhea and
rotavirus disease and the participants' perception of the
importance of these diseases. Participants were asked to
rank the seriousness of rotavirus disease on a scale of one
to seven, with one being "not serious at all" and seven
being "very serious." Lastly, participants reviewed the
rotavirus Vaccine Information Statement and discussed
their knowledge, issues, concerns, and attitudes towards
rotavirus vaccines. On a scale of one to seven, where one
was "definitely not get" and seven was "definitely get,"
participants were asked to rank their likelihood of having
their child vaccinated against rotavirus. To facilitate and
focus the discussion, throughout the session, the modera-
tor used flipcharts and printed handouts relevant to rota-
virus disease.
All provider interviews and consumer focus group ses-
sions were audio-taped and conducted in English during
March 2006, by independent moderators from a market
research facility (Market Directions, Inc.). Study investiga-
tors and data recorders were present behind a one-way
mirror and were available to answer questions at the end
of each session or interview. All participants were pro-
vided a moderate reimbursement for their time. The study
was reviewed and approved by CDC's Institutional
Review Board.
Results
Overall, we enrolled 10 providers and 57 consumers in
our study with varying levels of education, training, and
experience; diverse racial and ethnic backgrounds; and
broad levels of concern about vaccine safety issues (Tables
1 and 2). Below, we present the data stratified according
to the two groups of study participants.
Providers
All providers recognized the importance and impact of
severe dehydration from diarrheal disease and reported a
similar treatment algorithm that depended on the severity
of the dehydration. With regard to the vaccines, several
consistent themes emerged from the in-depth provider
interviews (Table 3) that can be categorized as: (1) vaccine
perception; (2) future utilization of vaccine; and (3) vac-
cine informational material.
Vaccine perception
Overall, all physicians were familiar with Rotashield and
the new vaccine, RotaTeq. Participants anticipated that
Rotashield's intussusception history would contribute to
the general anti-vaccine sentiment that is expressed by a
Table 2: Characteristics of consumers participating in the study, 
by study location
Characteristics Study site
Sunnyvale, 
California (N = 26)
Kansas City, 
Missouri (31)
Education
High school or less 5 10
More than high school 21 21
Race/ethnicity
White 9 20
Black 5 9
Asian American 3 0
Hispanic 6 1
Other 3 1
Focus group strata*
LOC high & CR yes 8 6
LOC high & CR no 7 9
LOC low & CR yes 7 8
LOC low & CR no 5 8
*LOC denotes level of concern about the safety of childhood vaccines 
(i.e., "high" or "low") and CR denotes child-rearing experience raising 
> 1 child to age 6 (i.e., "yes" or "no").
Table 1: Characteristics of providers participating in the study, 
by study location
Characteristics Study site
Sunnyvale, California 
(N = 5)
Kansas City, 
Missouri (N = 5)
Specialty
Pediatrics 3 3
Family medicine 2 2
Race/ethnicity
White 3 4
Asian American 2 1
Gender
Male 3 4
Female 2 1
Years in practice
<10 years 1 3
≥10 years 4 2BMC Pediatrics 2007, 7:32 http://www.biomedcentral.com/1471-2431/7/32
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small minority of their patients. However, all physicians
accepted RotaTeq as having an excellent safety and effi-
cacy profile and welcomed the incorporation of the vac-
cine into the routine immunization schedule. With regard
to parental acceptance, physicians predicted that the vac-
cine's safety and efficacy would be well-perceived by the
parents, but they also predicted that the "live" nature of
the vaccine and the history of Rotashield would be a
potential barrier to acceptance for some parents.
Future utilization of vaccine
When asked to rate their likelihood of using the new vac-
cine on a scale of one to seven, with one being "absolutely
not" and seven being "absolutely yes," the mean score was
5 (range = 3 to 6). Nonetheless, all providers remarked
that they would recommend the rotavirus vaccine to par-
ents if recommended for use by the ACIP and their respec-
tive professional organizations (i.e., Academy of Family
Practice and American Academy of Pediatrics). The gen-
eral sentiment was that once the vaccine became part of
the routine immunization schedule, they would spend
very little time discussing or promoting the individual
vaccine and the vaccine would likely be administered to
all eligible children. A majority of the physicians also
relayed an unaided response voicing a keen interest in fol-
lowing studies that continue to shed light on post-licen-
sure effectiveness and safety of the vaccine.
Vaccine information material
All physicians reviewed the CDC's Vaccine Information
Statement and found the content to be comprehensive,
clear, and useful for the parents.
When asked, none recommended any specific modifica-
tions for the Vaccine Information Statement.
Consumers
Among prospective consumers of the vaccine, a lack of
awareness about rotavirus disease and need for more
information about the disease and the vaccine was evi-
dent. General themes emerging from the focus groups can
be classified according to: (1) rotavirus knowledge; (2)
rotavirus vaccines; and (3) informational material.
Rotavirus knowledge
Prior to receiving printed informational material describ-
ing rotavirus disease and prevention through vaccination,
most participants were not aware of the public health
impact of rotavirus or its potential for causing severe dis-
ease and death. Participants did not rate the disease to be
a high-priority health issue for children. In Sunnyvale,
most participants reported never having heard of rotavirus
prior to the focus group. However, in Kansas City, where
a seasonal peak in rotavirus disease was ongoing at the
time of the focus group, an increased awareness of rotavi-
rus disease was noted among the participants. Perceived
seriousness of rotavirus diseases was somewhat greater in
Sunnyvale among women without child-rearing experi-
ence. Interestingly, once participants reviewed the Vaccine
Information Statement, most considered rotavirus disease
to be a moderately serious condition. Based on a scale of
1 ("not at all serious") to 7 ("very serious"), 59% consider
the seriousness of rotavirus disease to be very serious
(range 5 to 7), while 36% consider the disease to be mod-
erate (range = 3 to 4) and only 5% consider it to be not at
all serious (range = 1 to 2) (Figure 1).
Table 3: Consistently emerging themes from the provider interviews and the consumer focus groups – Sunnyvale, CA and Kansas City, 
MO.
Provider interviews:
• All physicians were familiar with Rotashield.
• Vaccine regarded as having an excellent safety and efficacy profile.
• Providers accurately predicted parental perception of vaccine safety and efficacy.
• Physicians likely to use RotaTeq if recommended by the Advisory Committee on Immunization Practices (ACIP).
• CDC's Vaccine Information Sheet noted to be accurate and useful for parents.
• All physicians reported a consistent treatment algorithm for diarrhea.
• Expressed interest in post-licensure safety and effectiveness data.
Consumer focus groups:
• Overall, rotavirus disease was not perceived to be a high-priority childhood health issue.
• Vaccine found to be acceptable and perceived in a positive light
• Vaccine concerns included: administration of a live-virus, "newness" of the vaccine, potential for adverse events, and narrow window of 
opportunity to vaccinate.
• Noted desire for more information with regard to rotavirus disease and vaccines.
• 16% of the consumers claimed that their child would "definitely not get" the vaccine.
• Physician's recommendation to vaccinate their child would be persuasive.BMC Pediatrics 2007, 7:32 http://www.biomedcentral.com/1471-2431/7/32
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Rotavirus vaccines
Upon reviewing the Vaccine Information Statement, con-
sumers generally deemed the vaccine to be acceptable and
commented positively on several aspects of the vaccine
such as the oral formulation, high efficacy in preventing
severe disease, administration of the vaccine during rou-
tinely scheduled physician visits, and overall safety of the
vaccine. However, when asked to rank the likelihood of
having their child vaccinated against rotavirus from 1
("definitely not get") to 7 ("definitely get"), 29% ranked
between 1 to 2, 36% between 3 to 4, and 35% between 5
to 7 (Figure 1). Generally, those participants with previ-
ous child-rearing experience were less concerned about
vaccinations. However, two respondents expressed
increased level of awareness with regard to vaccine safety
issues with their second child. Commonly expressed con-
cerns about the vaccine included the administration of a
live-vaccine to "young, vulnerable" infants, the newness
of the vaccine, potential for adverse events as more data
becomes available, and the narrow window of age when
the vaccine is recommended. Despite these concerns,
most consumers reported that they would rely on their
physician's recommendation on whether their child
should receive the rotavirus vaccine.
Informational material
In general, the rotavirus Vaccine Information Statement
generated interest and raised awareness about rotavirus
disease among the consumers, but it also raised more
questions about the biology and epidemiology of rotavi-
rus disease and reasons for not vaccinating beyond six
months of age. Consumers expressed a desire for more
information about rotavirus disease and identified the
Internet as a primary source of obtaining health informa-
tion. Study participants expressed preference for market-
ing websites such as WebMD.com and babycenter.com
and few recognized CDC as a source of source of health
information for the public.
Discussion
Our qualitative assessment using focus groups and in-
depth interviews of prospective rotavirus vaccine consum-
ers and providers, respectively, provided several valuable
insights about potential barriers to immunizing US chil-
dren against rotavirus and identified issues that need to be
better assessed through quantitative surveys. Most provid-
ers appreciated the health burden of rotavirus disease and
the need for a vaccine. While they were aware of the safety
issues with the previous rotavirus vaccine, they felt reas-
sured by the safety profile of the new rotavirus vaccine and
expressed a high likelihood of adopting the new vaccine,
particularly if it were recommended by their professional
organizations. In addition, most providers expressed spe-
cific interest in following results of the post-licensure vac-
cine effectiveness studies and data from adverse events
monitoring. This suggests that post-marketing surveil-
lance for effectiveness and safety should be a high priority
for the public health and research community and the
results should be rapidly communicated to providers.
Unlike physicians, however, women who participated in
these focus groups were considerably less aware of the
health burden of rotavirus. In our study, many focus
group participants, particularly those living in Sunnyvale,
were completely unaware about rotavirus disease.
Although these women initially did not perceive rotavirus
diarrhea to be a high-priority health issue, a majority con-
sidered rotavirus to be a moderate to severe illness after
reading the Vaccine Information Statement. Furthermore,
they asked many pertinent questions about the epidemi-
ology of rotavirus and risk factors for severe disease. Lack
of disease awareness may be one barrier to acceptance of
the new vaccine, particularly if parents perceive the risks
of vaccination to be greater [9,10]. Nevertheless our data
suggest that regardless of rotavirus knowledge, if the pro-
vider recommends vaccination, parents would likely
accept the vaccine. Because providers stated that they
would follow recommendations from ACIP and their pro-
fessional organizations, dissemination of rotavirus vac-
cine and disease information through these organizations
could be important to increase vaccine uptake. However,
further studies would be necessary to assess whether these
interventions actually contribute towards increasing vacci-
nation coverage rates.
Further exploration for the reasons for the lack of con-
sumer familiarity with rotavirus disease suggests that tra-
ditional media venues used by public health and medical
communities to disseminate information may not be
Consumer perception of the seriousness of rotavirus disease  and likelihood of getting the vaccine for their children Figure 1
Consumer perception of the seriousness of rotavirus 
disease and likelihood of getting the vaccine for their 
children. *Data missing on 1 participant. †Data missing for 2 
participants.
0%
5%
16%
20%
29%
14%
16% 16%
13%
18% 18% 16%
11%
7%
0
5
10
15
20
1234567
Ranking
N
u
m
b
e
r
 
o
f
 
P
a
r
t
i
c
i
p
a
n
t
s
Number of consumers (n=56*) ranking the seriousness of rotavirus disease on
a scale of 1 (not serious) to 7 (very serious)
Number of consumers (n=55†) assigning likelihood of getting the rotavirus
vaccine for their children on a scale of 1 (definitely not get) to 7 (definetly get).BMC Pediatrics 2007, 7:32 http://www.biomedcentral.com/1471-2431/7/32
Page 6 of 6
(page number not for citation purposes)
reaching the target audience. In our study, most partici-
pants did not use or recognize the CDC portal as a source
of health information for the public, but reported using
online sources of health information that are managed by
private companies. Utilizing such broader channels to dis-
seminate health information may be necessary to raise the
public awareness about rotavirus disease. Interestingly,
Kansas City residents were more aware of rotavirus disease
than those living in Sunnyvale, possibly because, in Kan-
sas City, the study was conducted during the peak rotavi-
rus season.
Some limitations should be considered in interpretation
of the findings. First, we interviewed relatively few physi-
cians and consumers from two selected geographic loca-
tions. The unique characteristics of our study sample may
limit the application of these findings to a broader popu-
lation. For example, most of the participants in Sunnyvale
were unaware of rotavirus disease prior to their involve-
ment in the focus group. Secondly, qualitative surveys can
be limited by the subjective interpretation of the data and
should be verified through quantitative surveys of a large
and representative sample [8,11]. We observed, however,
a consistency in the responses from both providers and
participants which suggests that these findings may be
broadly applicable. Furthermore, the responses from the
providers are consistent with those observed in larger
national surveys of providers [6,7]. Our qualitative survey
methodology was also useful in identifying important
themes about rotavirus disease that were complementary
to findings of quantitative surveys and thus provide a
comprehensive assessment of barriers to rotavirus vacci-
nation.
In conclusion, the findings of our survey indicate that US
providers are aware of the health burden of rotavirus and
are likely to adopt the new rotavirus vaccine, even though
they were aware of the safety concerns with the earlier
rotavirus vaccine. Parents were substantially less aware of
rotavirus disease, although most expressed that they
would get their child vaccinated if their physician recom-
mended it.
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